Tag Archives: BR

November, 2015

  • 13 November

    AbbVie Submits Imbruvica Phase 3 Combination Data to FDA

    NORTH CHICAGO, Ill., Nov. 13, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for labeling considerations based on safety and efficacy results from the Phase III HELIOS (CLL3001) trial investigating …